SCHEMBL16322889

SCHEMBL16322889

CCn1c(=O)cc(NC(C)c2ccc(F)c(F)c2)[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2B6 P20813 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ IDH1 O75874 1/20 0.34
▸ PGR P06401 2/20 0.33
▸ MME P08473 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GPR139 Q6DWJ6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16322888 1.00 SMN1; SMN2 (0.47) SMN1; SMN2HTTCYP3A4CYP2B6ALDH1A1
SCHEMBL16322050 0.83 HTT (0.53) SMN1; SMN2HTTCYP3A4CYP2B6IDH1
SCHEMBL16322048 0.83 HTT (0.53) SMN1; SMN2HTTCYP3A4CYP2B6IDH1
SCHEMBL16324040 0.82 SMN1; SMN2 (0.69) SMN1; SMN2HTTCYP3A4CYP2B6ALDH1A1
SCHEMBL16324039 0.82 SMN1; SMN2 (0.69) SMN1; SMN2HTTCYP3A4CYP2B6ALDH1A1
SCHEMBL16321172 0.79 HTT (0.49) SMN1; SMN2HTTCYP3A4CYP2B6GRIN1
SCHEMBL16322196 0.79 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP3A4CYP2B6ALDH1A1
SCHEMBL16321171 0.79 HTT (0.49) SMN1; SMN2HTTCYP3A4CYP2B6GRIN1
SCHEMBL16322198 0.79 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP3A4CYP2B6ALDH1A1
SCHEMBL16321643 0.78 SMN1; SMN2 (0.53) SMN1; SMN2HTTCYP3A4CYP2B6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744664-A2 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MyoKardia, Inc. (US) 2026-05-20 — — EP disclosed
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2024-11-21 — — US disclosed
US-RE50050-E1 Pyrimidinedione compounds MyoKardia, Inc. (US) 2024-07-23 — — US disclosed
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2023-06-01 — — US disclosed
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2021-11-11 — — US disclosed
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2020-09-24 — — US disclosed
EP-3702352-A1 PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2020-09-02 — — EP disclosed
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2018-11-01 — — US disclosed
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2017-10-05 — — US disclosed
US-9585883-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2017-03-07 — — US disclosed
EP-3010910-A1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2016-04-27 — — EP disclosed
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2016-02-04 — — US disclosed
US-9181200-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2015-11-10 — — US disclosed
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2014-12-25 — — US disclosed
WO-2014205223-A1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MyoKardia, Inc. (US) 2014-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback